Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | TPH1 | P17752 | 1/20 | 0.38 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016921 | 0.89 | ADORA2B (0.41) | MAOBMAOANR3C1LMNAHTT | |
| SCHEMBL4019325 | 0.88 | LMNA (0.42) | MAOBMAOANR3C1LMNAHTT | |
| SCHEMBL4018480 | 0.79 | TPH1 (0.50) | HTTTPH1TPH2SMN1; SMN2 | |
| SCHEMBL5509419 | 0.78 | ADORA3 (0.44) | MAOBMAOANR3C1LMNAHTT | |
| SCHEMBL5061625 | 0.75 | TPH1 (0.48) | HTTTPH1TPH2SMN1; SMN2 | |
| SCHEMBL4016181 | 0.75 | MEN1 (0.42) | LMNAHTT | |
| SCHEMBL4014400 | 0.72 | ADORA2A (0.41) | PARP1 | |
| SCHEMBL16057858 | 0.71 | MAPT (0.45) | MAOBMAOAHTTCYP1A2 | |
| SCHEMBL4284406 | 0.70 | NOD1 (0.39) | DAOLMNAHTTSMN1; SMN2 | |
| SCHEMBL4016371 | 0.70 | ADORA2B (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009157938-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING CANCER | CV THERAPEUTICS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |